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Abstract 
Urothelial carcinomas have an established
propensity for divergent differentiation. Most
of these variant tumors are muscle invasive
but not all. The response of non muscle inva-
sive  variant  tumors  to  intravesical
immunotherapy with BCG is not established in
the literature, and is reported here. Between
June 1995 and December 2007, 760 patients
(mean  age  of  67.5  years)  underwent
transurethral  resection  of  first  time  bladder
tumors in our institution. Histologically vari-
ant tumors were found in 79 patients (10.4%).
Of these 57 patients (72%) of them had mus-
cle-invasive disease or extensive non-muscle
invasive  tumors  and  remaining  22  patients
(28%) were treated with BCG immunotherapy.
These included 7 patients with squamous dif-
ferentiation, 4 with glandular, 6 with nested, 4
with micropapillary and 1 patient with sarco-
matoid variant. The response of these patients
to immunotherapy was compared with that of
144 patients having high-grade conventional
urothelial carcinomas. Median follow-up was
46  months.  The  2  and  5-year  progression
(muscle-invasion)  free  survival  rates  were
92% and 84.24% for patients with conventional
carcinoma compared to 81.06% and 63.16% for
patients with variant disease (P=0.02). The 2
and 5-year disease specific survival rates were
97% and 91.43% for patients with conventional
carcinoma compared to 94.74 % and 82% for
patients  with  variant  disease  (P=0.33).  5
patients  (22.7%)  of  variant  group  and  13
patients (9.03%) of conventional group under-
went cystectomy during follow-up (P=0.068).
Patients with non-muscle invasive variants
of bladder cancers can be managed with intra-
vesical immunotherapy if tumor is not bulky
(>4 cm). Although progression to muscle inva-
sive disease is more common than in conven-
tional group and occurs in about 40% of the
patients, life expectancy is similar to patients
with conventional high-grade urothelial carci-
nomas provided that follow-up is meticulous.
Introduction 
Urothelial carcinomas have an established
propensity  for  differentiation  into  several
types of variant tumors. Most of these tumors
are high-grade and muscle invasive. The mor-
phological features of these tumors are well
documented and they are often associated with
poor prognosis.1 It is still unclear however, if
this is related to variant histology itself or to
the  high  grade  and  stage  typical  to  these
tumors.1Several studies suggested that variant
tumors  also  respond  poorly  to  surgery,
chemotherapy or radiation therapy.1-3
Although most of the variant tumors invade
the muscularis propria or are very bulky (>4
cm), some of these tumors are limited to the
lamina  propria  and  can  be  fully  resected
transurethrally.  Can  these  patients  be  man-
aged with intravesical immunotherapy? In this
study  we  compared  the  response  to  BCG
immunotherapy of patients with variant tumor
to  patients  with  conventional  high-grade
urothelial carcinoma. 
Materials and Methods 
Patient population 
An institutional database was retrospective-
ly obtained from the hospital registry which
contained  information  on  760  consecutive
patients who underwent transurethral resec-
tion  of  bladder  cancer  for  the  first  time
between  June  1995  and  December  2007.  All
pathological material was reviewed by a single
dedicated  uro-pathologist.  Pathologic  staging
was performed according to the TNM system
and grading according to the 1973 WHO classi-
fication.4 The study was approved by the IRB
(number 207-31.10.08). 
Treatment and follow-up protocol 
Treatment  protocol  included  second  look
resection  in  patients  with  either  pT1  or  G3
tumors. Patients with confirmed pT1, G3 or Tis
were  considered  eligible  for  immunotherapy
provided that all visible tumors were resected
and  second  look  biopsies  confirmed  pT0.
Immunotherapy protocol included an induction
course of 6 weekly (no less than 4) intravesical
instillations of 81 mg Connaught BCG in 50 cc
of normal saline, initiated 10-20 days following
surgery.  Maintenance  therapy  included  2-3
instillations every 3 months for one year and
then  every  6  months  for  additional  2  years.
Radical  cystectomy  was  offered  to  patients
with  disease  progression  to  T2,  to  patients
resistant  to  immunotherapy  or  in  cases  of
recurrent T1G3 or Tis tumors. 
Follow-up protocol included bladder biopsy
after the induction course, and then cystoscopy
and cytology every 3 months for 2 years and
every 6 months for another 3 years. Upper tract
surveillance  (intravenous  pyelography  and
more recently CT urography) was performed
on initial diagnosis and then annually. 
Statistical analysis 
The outcome of patients with variant histol-
ogy  receiving  BCG  immunotherapy  was  com-
pared to the outcome of patients with conven-
tional high grade urothelial carcinoma treated
with BCG immunotherapy. Continuous variables
were compared using t-test and categorical vari-
ables with Fischer’s exact test and chi square
tests.  Survival  analysis  was  done  using  the
Kaplan-Meier method. A p-value <0.05 was con-
sidered significant. Statistical analysis was done
using the JMP software (SAS Cary, NC, USA). 
Results
Study cohort comprised of 760 patients (mean
age 67.5 years, S.D. 12.7 years), including 622
men and 138 women. Tumor staging according
to specimens obtained at transurethral resection
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doi:10.4081/rt.2011.e22were: stage Ta in 478 patients (62.9%), stage T1
in  157  patients  (20.6%),  and  muscle-invasive
disease (stage >T2) in 112 patients (14.7%).
Grading  according  to  the  WHO,  1973  system
showed: grade 1 tumor in 166 patients (21.8%),
grade  2  in  276  (36.3%)  and  grade  3  in  318
(41.8%). Bladder carcinoma in situ (either pure
or concomitant) was found in 137 cases (18%).
Histological  variants  of  urothelial  carcinoma
were found in 79 patients (10.4%), and included:
squamous  differentiation  in  22  patients
(27.85%),  nested  in  20  patients  (25.32%),
micropapillary in 13 (16.45%), sarcomatoid in 15
patients  (19%)  and  glandular  in  9  patients
(11.39%).  Most  of  the  patients  with  variant
tumors had muscle invasive disease or a bulky
tumor  (>4  cm)  that  could  not  be  entirely
removed  transurethrally.  However,  in  22
patients,  tumor  was  non  muscle-invasive  and
was fully resectable as confirmed on second look
TURBT (Table 1). These patients received adju-
vant intravesical BCG immunotherapy. Among
these patients were: 7 patients with squamous
differentiation, 6 with nested, 4 with glandular, 4
with micropapillary and 1 patient with sarcoma-
toid variant (Figure 1).
The outcome of patients with variant histol-
ogy receiving BCG immunotherapy was com-
pared to the outcome of 144 patients with con-
ventional high grade urothelial carcinoma that
were treated with BCG immunotherapy (Table
2 and Figure 2). The groups were similar in
age, gender, stage distribution and follow-up
length. The 2 and 5 year recurrence free sur-
vival rates were 79.56% and 71.74% with con-
ventional carcinoma compared to 87.84% and
69.18% for the variant disease (P=0.68). The 2
and 5-year progression (muscle-invasion) free
survival  rates  were  92%  and  84.24%  for
patients  with  conventional  carcinoma  com-
pared to 81.06% and 63.16% for patients with
variant  disease  (P=0.02).  Median  time  of
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Figure 1. Photos of urothelial carcinoma histological variants not invading the detrusor
muscle (H&E, X100). (A) glandular variant (case 6), (B) micropapillary variant (case 3),
(C) nested variant (case 13), (D) Squamous variant (case 17).
Table 1. Demographics of the variant histology, prognosis and outcome.
Patient Age Sex Stage Grade Variant Recurrence Progression Outcome
1  85  M  pTa  2  Micropapillary  Nil  Nil  Died of IHD at 60 m 
2  88  M  pTa  3  Micropapillary  Nil  Nil  Died of IHD at 43 m 
3  64  M  pTa  3  Micropapillary  Nil  6  Died of UC at 26 m 
4  73  M  pT1  3  Micropapillary  Nil  Nil  NED, follow up 69 m 
5  68  M  pT1  3  Glandular  Nil  Nil  NED, follow up 20 m 
6  78  M  pTa  3  Glandular  Nil  Nil  NED, Follow up 49 m 
7  76  M  pTa  3  Glandular  Nil  Nil  NED, follow up 23 m 
8  81  M  pTa  3  Glandular  Nil  Nil  NED, follow up 18 m 
9  77  M  pT1  3  Nested  Nil  33  NED, 33 m, cystectomy 
10  77  M  pT1  3  Nested  37  37  NED, follow up 134 m 
11  78  F  pT1  3  Nested  47  Nil  NED, follow up 52 m 
12  44  M  pT1  3  Nested  41  Nil  NED, 68 m, cystectomy 
13  72  F  pTa  3  Nested  Nil  Nil  NED, follow up to 82 m 
14  56  M  pTa  2  Nested  18  Nil  NED, follow up to 87 m 
15  57  M  pTa  3  Sarcomatoid  Nil  14  Died of UC at 37 m 
16  64  M  pT1  3  Squamous  Nil  10  Died of UC at 23 m 
17  75  M  pT1  3  Squamous  Nil  Nil  NED, follow up 104 m 
18  53  F  pT1  3  Squamous  Nil  25  NED, 25 m , cystectomy 
19  82  M  pT1  3  Squamous  14  19  NED, 150 m, cystectomy 
20 58 M pT1 3 Squamous Nil Nil NED,  12 m, cystectomy
21 83 M pT1 3 Squamous Nil Nil NED, follow up 34 m
22 65 M pT1 3 Squamous Nil Nil NED, follow up 120 m
Age in years, Recurrence, occurrence of new tumor in months; Progression, upstaging to pT2 or muscle invasion in months; IHD, ischemic heart disease; UC, urothelial carcinoma; NED, no evidence of disease; 
UC, urothelial carcinoma; Lost to follow up cases – nil.[Rare Tumors 2011; 3:e22] [page 69]
progress to muscle-invasive disease was sig-
nificantly shorter in the patients with variant
disease (19.8 vs 56 months, P=0001). A total of
5/22 (22.7%) patients of the variant group and
13/144 (9.03%) of conventional group under-
went cystectomy (P=0.068) during the course
of disease follow-up. Among the variant group
a total of 7 patients had progression of disease.
Of these, 3 underwent cystectomy and all 3 are
surviving.  Of  the  remaining  4,  two  patients
received chemoradiation and among these 4,
only one is surviving and is under followup. In
the conventional group, a total of 18 patients
had  progression  of  disease.  Of  these,  9
patients underwent cystectomy and 6 of them
are surviving. Whereas in the non cystectomy
group (9patients), two received chemoradia-
tion and 3 patients are surviving.
The 2 and 5-year disease specific survival
rates however, were not significantly different
(97% and 91.43% for patients with convention-
al carcinoma and 94.74 % and 82% for patients
with variant disease, P=0.33). 
Discussion
Histological variants of urothelial carcinoma
are not uncommon. In the current study vari-
ant  tumors  were  found  in  10.4%  of  the
patients. The most common variants are the
squamous, nested, micropapillary, sarcomatoid
and  the  glandular  types.  These  tumors  are
invariably  high-grade  and  most  commonly
invade the detrusor muscle and are associated
with poor prognosis. The presence of variant
histology  is  considered  an  independent  risk
factor for extravesical disease but not for dis-
ease  specific  mortality.5 Radical  cystectomy,
with or without neoadjuvant chemotherapy is
advised to most patients with variant tumors
and most of the literature on variant tumors
reports on patients’ prognosis after radical cys-
tectomy.2,5-7 There  is  however,  a  group  of
patients with variant tumors that do not invade
the  detrusor  and  that  can  be  removed  com-
pletely transurethrally. There is paucity in lit-
erature regarding the use of BCG in non-mus-
cle invasive disease of variant histology. 
In  this  study,  patients  with  completely
resectable variant tumors (confirmed by sec-
ond  look  biopsies)  were  treated  with  BCG
immunotherapy. Their outcome was compared
to  patients  with  conventional  high-grade
urothelial cancer treated with BCG. The groups
were similar in age, gender distribution, stage
and follow-up length. It was found that variant
tumors are associated with higher progression
rate but with similar disease specific survival. 
Regarding the various variant tumors, squa-
mous differentiation is one of the commonest
histological variants of UC. After radical cys-
tectomy, the finding of squamous differentia-
tion  increases  the  likelihood  of  local  recur-
rence.6,8Beside case reports, there are no stud-
ies of the response of these variant tumors to
BCG. In our study, 7 patients with squamous
differentiation were followed for median peri-
od  of  34  months  after  BCG  administration.
Three  had  tumor  progression,  of  which  2
patients had radical cystectomy and are under
follow-up, where as 1 patient died from UC.
Nested carcinoma is another variant of the
UC. About 70 cases have been reported mostly
in the form of case reports.1Early cystectomy is
recommended by most authorities.9 In the cur-
rent study, 6 patients with the nested variant
did rather well. After a median follow-up of 75
months, 2 patients were found to have tumor
progression, of which one patient underwent
radical  cystectomy  and  other  underwent
chemo radiation but none died from UC. 
The  micropapillary  bladder  cancer  is  an
aggressive variant of UC. In the current series,
4  patients  with  micropapillary  variant  who
received BCG were followed for a median peri-
od of 52 months. One patient developed pro-
Article
Table 2. Comparison of demographics with important events between the variant and conventional histologies.
Parameters Variant Conventional P
Number of patients  22  144  - 
Age (Mean ± Stdev)  70.72±11.7  68.62±10.6  0.4 
Gender (M : F )  19: 3 (86.4%:13.6%)  127: 17 (88.2%: 11.8%)  0.73 
Median FU  46 m  50 m  0.83 
Stage (Ta, T1)  9(41%), 13(59%)  46(32%), 98(68%)  0.47
Recurrence  5/22 (22.73%)  38/144(26.39%)  0.68 
Median time to recurrence  35.5 m  37 m  0.23 
Progression to pT2  7/22 (31.82%)  18/144 (12.5%)  0.02 
Median time to progression (pT2)  19.8 m  56 m  0.0001 
2 years disease specific survival  94.74%  96.98%  0.33 
5 years disease specific survival  81.98%  91.43%  0.33 
Patients underwent cystectomy  5/22 (22.7%)  13/144 (9.03%)  0.068 
No of disease-specific deaths  3/22 (13.64%)  10/144(6.94%)  0.83 
Figure  2.  Kaplan-Meier  curves  for  (A)
Recurrence  free  survival  (P=0.6762).  (B)
Progression  (to  stage  =>T2)  free  survival
(P=0.02).  (C)  Disease-specific  survival
(P=0.3378).[page 70] [Rare Tumors 2011; 3:e22]
gression, who received chemo radiation with-
out cystectomy but died at 26 months. In the
largest series of micropapillary bladder cancer,
Kamat  et  al  reported  on  27  patients  who
received BCG for non-muscle invasive disease.
Only 17% of them remained disease free after
a median follow-up of 30 months10 leading the
investigators  to  the  conclusion  that  BCG
immunotherapy is ineffective against this dis-
ease.11
The glandular variant of UC was found in
only 4 patients in the current series. After a
median follow-up of 22 months, none devel-
oped  recurrence  or  progression.  The  largest
series of noninvasive UC with glandular differ-
entiation was reported by Miller and Epstein.12
In  that  series,  7  patients  were  treated  with
BCG and follow-up was available in 6. None
developed recurrence. The sarcomatoid carci-
noma  is  typically  locally  or  systemically
advanced  disease  with  poor  prognosis  com-
pared to patients with conventional carcinoma
in a similar stage.1 A single patient with a sar-
comatoid variant was given BCG in the current
series. He developed tumor progression after
14 months and died of metastatic disease at 37
months.  There  are  no  reports  in  literature
regarding the effectiveness of BCG in this vari-
ant. Aggressive multimodality treatment with
neoadjuvant chemotherapy and radical surgery
is probably the best therapy for this disease
and not BCG immunotherapy.2 To summarize,
our study suggests that intravesical BCG has a
role in treating selected patients with variant
histology tumors that are non bulky (<4 cm)
and  completely  resectable  transurethrally.
Patients  with  glandular,  squamous  and  the
nested variants respond reasonably well to this
therapy, while the micropapillary variant tends
to progress despite treatment. The study is lim-
ited by the small number of patients and by
being  single  institutional  and  retrospective.
The  combined  analysis  of  several  variant
tumors together, although a common method-
ology,5,7,13 is another limiting factor.  
Conclusions  Patients  with  non-muscle
invasive  variants  of  bladder  cancers  can  be
managed  with  intra-vesical  immunotherapy
with BCG provided the tumor is not bulky, can
be  completely  removed  transurethrally  and
this  is  confirmed  by  second  look  biopsies.
Higher  progression  rate  to  muscle  invasive
disease is expected compared to conventional
urothelial carcinoma. However, when follow-
up is meticulous, life expectancy is similar to
patients with high-grade conventional urothe-
lial  carcinomas  treated  with  intravesical
immunotherapy. A patient choosing this ther-
apy must be aware of the high risk of progres-
sion and disease specific mortality, and should
be highly motivated to comply with the follow-
up protocol.
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